Abstract:Background While the past decades have seen an explosion of innovation in immunotherapies, most have failed in their clinical studies. One of the barriers encountered across these trials is that despite demonstrated cytoxicity, tumor immune evasion renders these treatments ineffective. Glioblastoma (GBM) is one of these tumors where experimental immunotherapeutics have continued to fail. The median survival of GBM remains at 15 months with the primary treatment being surgical resection, radiation, and chemotherapeutic over the past decade. To breach this stalemate, we require new therapeutics that both can target tumor immune evasion and can balance efficacy with toxicity. Our lab previously developed a subcutaneous autologous tumor vaccine utilizing a phagocytosis-stimulating ligand mannan anchored to irradiated (IR) tumor cells with the adjuvants toll-like receptor (TLR) agonists and immunostimulant anti-CD40 antibody (collectively abbreviated as MBTA). This regime allowed recognition of tumors resulting in a coordinated innate and adaptive immune response in both prophylactic and therapeutic studies with colon carcinoma, breast tumor, and GBM mouse models. The aim of our study was to generate a dendritic cell (DC) vaccine utilizing this strategy. Methods To assess if MBTA anchored GBM cells could mature DCs in-vitro, we harvested bone-marrow DCs (BMDCs) from mice and co-cultured them with MBTA GBM cells for 24 hours. Analysis was performed by flow cytometry and ELISA to confirm maturation markers and DC phenotype. To assess if MBTA DCs could protect against tumor metastasis, we utilized a melanoma (B16) prophylactic model by vaccinating mice 1 week before tail vein melanoma challenge. Results We found robust up-regulation of co-stimulatory molecules CD40, CD80 and CD86 and preferential upregulation of MHCI in the MBTA group with ELISA analysis demonstrating MBTA DCs significantly upregulated Type 1 cytokines (TNFa and IL-6) and limited regulatory cytokine (IL-10) secretion across GBM cell lines. Mice vaccinated with MBTA DCs had a significant decrease in lung metastasis compared to controls with lung immunohistochemistry demonstrating robust perivascular lymphocytic infiltration. Currently, we are working on demonstrating this efficacy in a glioblastoma model. Conclusions Collectively our results demonstrate that MBTA is an effective strategy to mature and load tumor antigens onto DCs ex-vivo. It has efficacy as a DC vaccine to prevent melanoma metastasis and potential as a glioblastoma DC vaccine. Acknowledgements The authors acknowledge the NCI-CCR affiliated staff for their assistance with animal housing and the NCI CCR Flow Cytometry Core Members for their expertise in flow cytometry Ethics Approval The National Cancer Institute (NCI) Animal Use and Care Committees approved the present study under NOB-010 and NOB-016.

Efficacy of Antiangiogenic Targeted Immunotoxin DTAT and DTATEGF Against Glioblastoma Multiforme.

Specific T Cell Immunotherapy Against Glioblastoma with Mouse Model

The Antitumor Effect of TAT-DCF1 Peptide in Glioma Cells

Immunotherapy of Intracranial G422 Glioblastoma with Dendritic Cells Pulsed with Tumor Extract or RNA

425 A Novel Dendritic Cell Vaccine Utilizing Mannan Anchored to Irradiated Tumor Cells in the Presence of Immune Adjuvants

Antitumor treatment efficacy by targeting epidermal growth factor receptor and vascular endothelial growth factor receptor-2 in an orthotopic human glioblastoma model

Tumor protease-activated theranostic nanoparticles for MRI-guided glioblastoma therapy

A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone-based OKN-007

Tumor cells and neovasculature dual targeting delivery for glioblastoma treatment

Dddr-38. Translational Steps Of The Antitumor Peptide Tat-Cx43266-283 As A Treatment For Glioblastoma: Egfr As A Treatment Response Biomarker And Results Of Combination Therapy In A Preclinical Resection Model

Anti-tumor Effect of Integrin Targeted 177Lu-3Prgd2 Radionuclide Therapy by a Combined Treatment with Angiogenesis Inhibitor, Endostar, in Human Glioblastoma Xenograft

Ddel-16. Micromesh For Revamping The 'Cold' Tumor Microenvironment In Glioblastoma Immunotherapy

Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme

The Inhibitive Effect of Targeting Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 on Transplanted Human Glioblastoma Multiforme in Nude Mice

Targeted Alpha Therapy of Glioma Using 211At-Labeled Heterodimeric Peptide Targeting Both VEGFR and Integrins

Combination therapy with antiangiogenic treatment and photodynamic therapy for the nude mouse bearing U87 glioblastoma.

Toxic warhead-armed antibody for targeted treatment of glioblastoma

Integrin Alpha(V)Beta(3)-Targeted Radioimmunotherapy Of Glioblastoma Multiforme

Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme

Highly Efficacious and Specific Anti-Glioma Chemotherapy by Tandem Nanomicelles Co-Functionalized with Brain Tumor-Targeting and Cell-Penetrating Peptides

Investigation of a Plasmid Containing a Novel Immunotoxin VEGF165‐PE38 Gene for Antiangiogenic Therapy in a Malignant Glioma Model